Legend Biotech Q2 Earnings Call Highlights

2 weeks ago 11

MarketBeat

Tue, August 11, 2026 astatine 8:04 AM CDT 6 min read

CPI Data Sparks Rally successful Biotech Stocks

Legend Biotech (NASDAQ:LEGN) reported second-quarter 2026 results marked by continued planetary maturation for CARVYKTI and the company's archetypal 4th of company-wide profitability connected some an IFRS and adjusted basis, absorption said during its net call.

Interim Chief Executive Officer Alan Bash said the institution generated astir $657 cardinal successful worldwide nett commercialized income for CARVYKTI during the quarter, up 50% from a twelvemonth earlier and 10% sequentially. He besides said Legend generated adjusted nett income of $63 cardinal and expects to stay adjusted-net-income profitable during the 2nd fractional of 2026.

→ SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat

Why Legend Biotech Stock Is Having Its Best Month Yet

The telephone followed the departure of erstwhile CEO Dr. Ying Huang past month. Bash said the enactment alteration does not correspond a alteration successful strategy, with the institution remaining focused connected expanding CARVYKTI, advancing its next-generation pipeline and strengthening execution.

CARVYKTI Growth Driven by Earlier-Line Use and International Expansion

CARVYKTI income successful the U.S. accrued 32% twelvemonth implicit year, portion income extracurricular the U.S. roseate 128%, according to Bash. U.S. income grew 9% sequentially, supported chiefly by accelerating adoption successful earlier attraction lines. International income accrued 13% sequentially arsenic launches continued crossed 19 markets and the institution expanded its activated treatment-site network.

→ Quantum Earnings Week: Winners and Losers Are Finally Emerging

Legend said CARVYKTI is present disposable done 348 attraction sites globally. More than 150 authorized attraction centers are successful the U.S., including assemblage hospitals representing astir 40% of those sites.

Management said usage successful the 2nd done 4th lines of attraction present accounts for much than 70% of CARVYKTI's U.S. volume. The institution had antecedently said second- and third-line usage represented 41% of full mix, but said it does not program to supply that much elaborate breakout each quarter.

→ Take-Two's Q1 Results Leave GTA 6 Bulls Stuck successful the Fog of War

Bash said the institution and its partner, Johnson & Johnson, proceed to presumption CARVYKTI arsenic a "one-and-done" attraction enactment compared with continuous therapies. Management besides cited objective and real-world information suggesting patients whitethorn person amended outcomes erstwhile they person CAR-T therapy earlier different BCMA-directed attraction options.

Legend reiterated its presumption that CARVYKTI has highest yearly income imaginable supra $5 billion.

Read Entire Article